TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label, Randomized, Controlled Multi-Center Study of The Efficacy of Daromun (L19IL2 + L19TNF) Neoadjuvant Intratumoral Treatment Followed by Surgery and Adjuvant Therapy Versus Surgery and Adjuvant Therapy in Clinical Stage IIIB/C Melanoma Patients
Brief Summary: The trial aims to evaluate the efficacy of Daromun neoadjuvant treatment followed by surgery and adjuvant therapy to improve in a statistically significant manner the recurrence-free survival (RFS) of Stage IIIB/C melanoma patients with respect to the standard of care (surgery and adjuvant therapy).


Options:
A: Arm Label: Arm A consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab - Arm A | Arm Label: Arm B consists of 3 phases or steps; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab + Ipilimumab - Arm B | Intervention Type: DRUG; Name: Nivolumab - Arm A; Assigned to Arm(s): Arm A consists of 3 phases or steps | Intervention Type: DRUG; Name: Nivolumab + Ipilimumab - Arm B; Assigned to Arm(s): Arm B consists of 3 phases or steps
B: Arm Label: Daromun plus Surgery and Adjuvant therapy (Arm 1); Type: EXPERIMENTAL; Interventions: Drug: Daromun, Procedure: Surgery, Drug: Adjuvant therapy | Arm Label: Surgery and adjuvant therapy (Arm 2); Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery, Drug: Adjuvant therapy | Intervention Type: DRUG; Name: Daromun; Assigned to Arm(s): Daromun plus Surgery and Adjuvant therapy (Arm 1) | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Daromun plus Surgery and Adjuvant therapy (Arm 1), Surgery and adjuvant therapy (Arm 2) | Intervention Type: DRUG; Name: Adjuvant therapy; Assigned to Arm(s): Daromun plus Surgery and Adjuvant therapy (Arm 1), Surgery and adjuvant therapy (Arm 2)
C: Arm Label: Arm 1: neoadjuvant + surgery; Type: EXPERIMENTAL; Interventions: Drug: L19IL2 + L19TNF, Procedure: Surgery | Arm Label: Arm 2: surgery alone; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery | Intervention Type: DRUG; Name: L19IL2 + L19TNF; Assigned to Arm(s): Arm 1: neoadjuvant + surgery | Intervention Type: PROCEDURE; Name: Surgery; Assigned to Arm(s): Arm 1: neoadjuvant + surgery, Arm 2: surgery alone
D: Arm Label: vemurafenib + cobimetinib + atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Vemurafenib, Drug: Cobimetinib, Drug: Atezolizumab | Intervention Type: DRUG; Name: Vemurafenib; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab | Intervention Type: DRUG; Name: Cobimetinib; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): vemurafenib + cobimetinib + atezolizumab

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Trial on Comparison of Cervical Spine Motion During Tracheal Intubation Using Direct Laryngoscope Versus C-MAC Videolaryngoscope in Simulated Immobilized Cervical Spine
Brief Summary: The aim of the study is to compare the effect of the C-MAC videolaryngoscope intubation technique vs. the conventional direct laryngoscope intubation technique on the cervical spine motion during intubation in patients with the simulated cervical immobilization.


Options:
A: Arm Label: Intubation c McGrath videolaryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Device: McGrath | Arm Label: Intubation using Macintosh Laryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Device: Tracheal intubation using Macintosh Laryngoscope | Intervention Type: DEVICE; Name: McGrath; Assigned to Arm(s): Intubation c McGrath videolaryngoscope | Intervention Type: DEVICE; Name: Tracheal intubation using Macintosh Laryngoscope; Assigned to Arm(s): Intubation using Macintosh Laryngoscope
B: Arm Label: Videolaryngoscope McGrath Mac; Type: ACTIVE_COMPARATOR; Interventions: Device: Videolaryngoscope | Arm Label: Standard laryngoscope; Type: PLACEBO_COMPARATOR; Interventions: Device: Standard laryngoscope | Intervention Type: DEVICE; Name: Videolaryngoscope; Assigned to Arm(s): Videolaryngoscope McGrath Mac | Intervention Type: DEVICE; Name: Standard laryngoscope; Assigned to Arm(s): Standard laryngoscope
C: Arm Label: Macintosh laryngoscope; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Tracheal intubation, Drug: Propofol and remifentanil anesthesia | Arm Label: McGrath Mac videolaryngoscope; Type: EXPERIMENTAL; Interventions: Procedure: Tracheal intubation, Drug: Propofol and remifentanil anesthesia | Intervention Type: PROCEDURE; Name: Tracheal intubation; Assigned to Arm(s): Macintosh laryngoscope, McGrath Mac videolaryngoscope | Intervention Type: DRUG; Name: Propofol and remifentanil anesthesia; Assigned to Arm(s): Macintosh laryngoscope, McGrath Mac videolaryngoscope
D: Arm Label: Group A; Type: EXPERIMENTAL; Interventions: Device: C-MAC videolaryngoscope intubation, Device: Direct laryngoscope intubation | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Device: C-MAC videolaryngoscope intubation, Device: Direct laryngoscope intubation | Intervention Type: DEVICE; Name: C-MAC videolaryngoscope intubation; Assigned to Arm(s): Group A, Group B | Intervention Type: DEVICE; Name: Direct laryngoscope intubation; Assigned to Arm(s): Group A, Group B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Non-Inferiority Trial ComparingCigarette Consumption, Adoption Rates, Acceptability, Tolerability, and Tobacco Harm Reduction Potential in Smokers Switching to Heated Tobacco Products or Electronic Cigarettes: Study Protocol
Brief Summary: This is a 12-weeks, open label, non-inferiority trial comparing HTPs vs ECs in terms of efficacy, adoption rate and acceptability, tolerability, and tobacco harm reduction in 220 healthy smokers, not motivated to quit, randomized (1:1) to switch to one of these products. The duration of the study, from the enrollment to the study close out for all the patients at week 24 (follow-up), will be approximately 12 months. Enrollment period will last about 6 months with the support of a multi-channel advertising method. This will include location-based advertising on social networks, advertising in local media, information days organized within the city.


Options:
A: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)
B: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
C: Arm Label: Healthy Control - Non-smoking; Type: OTHER; Interventions: Other: Biological Control | Arm Label: Healthy Control - Smoker; Type: OTHER; Interventions: Other: Biological Control | Arm Label: HIV Smoking Cessation Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline tartrate, Drug: Nicotine Replacement Therapy | Arm Label: Motivational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: DRUG; Name: Nicotine Replacement Therapy; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: OTHER; Name: Biological Control; Assigned to Arm(s): Healthy Control - Non-smoking, Healthy Control - Smoker | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Motivational Intervention
D: Arm Label: Ecig 24 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: Ecig 24 mg nicotine | Arm Label: Ecig 0 mg nicotine; Type: SHAM_COMPARATOR; Interventions: Device: Ecig 0 mg nicotine | Arm Label: Nicotine free inhalator; Type: PLACEBO_COMPARATOR; Interventions: Device: Nicotine free inhalator | Intervention Type: DEVICE; Name: Ecig 24 mg nicotine; Assigned to Arm(s): Ecig 24 mg nicotine | Intervention Type: DEVICE; Name: Ecig 0 mg nicotine; Assigned to Arm(s): Ecig 0 mg nicotine | Intervention Type: DEVICE; Name: Nicotine free inhalator; Assigned to Arm(s): Nicotine free inhalator

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Non-Inferiority Trial ComparingCigarette Consumption, Adoption Rates, Acceptability, Tolerability, and Tobacco Harm Reduction Potential in Smokers Switching to Heated Tobacco Products or Electronic Cigarettes: Study Protocol
Brief Summary: This is a 12-weeks, open label, non-inferiority trial comparing HTPs vs ECs in terms of efficacy, adoption rate and acceptability, tolerability, and tobacco harm reduction in 220 healthy smokers, not motivated to quit, randomized (1:1) to switch to one of these products. The duration of the study, from the enrollment to the study close out for all the patients at week 24 (follow-up), will be approximately 12 months. Enrollment period will last about 6 months with the support of a multi-channel advertising method. This will include location-based advertising on social networks, advertising in local media, information days organized within the city.


Options:
A: Arm Label: E-Cigarette; Type: EXPERIMENTAL; Interventions: Other: E-Cigarette Vs. Smoking as Usual | Arm Label: Assessment Only; Type: ACTIVE_COMPARATOR; Interventions: Other: E-Cigarette Vs. Smoking as Usual | Intervention Type: OTHER; Name: E-Cigarette Vs. Smoking as Usual; Assigned to Arm(s): Assessment Only, E-Cigarette
B: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
C: Arm Label: Electronic cigarette with or without nicotine; Type: ACTIVE_COMPARATOR; Interventions: Other: Electronic cigarette | Arm Label: Smoker control; Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional cigarette | Intervention Type: OTHER; Name: Electronic cigarette; Assigned to Arm(s): Electronic cigarette with or without nicotine | Intervention Type: OTHER; Name: Conventional cigarette; Assigned to Arm(s): Smoker control
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Arm Label: E-cigarette free access; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette free access | Arm Label: E-cigarette/NRT/Zyban/Chantix Choice; Type: EXPERIMENTAL; Interventions: Behavioral: E-cigarette/NRT/Zyban/Chantix Choice | Arm Label: Outcome Incentive arm; Type: EXPERIMENTAL; Interventions: Behavioral: Outcome Incentive arm | Arm Label: Loss framing incentive arm; Type: EXPERIMENTAL; Interventions: Behavioral: Loss framing incentive arm | Intervention Type: BEHAVIORAL; Name: E-cigarette free access; Assigned to Arm(s): E-cigarette free access | Intervention Type: BEHAVIORAL; Name: E-cigarette/NRT/Zyban/Chantix Choice; Assigned to Arm(s): E-cigarette/NRT/Zyban/Chantix Choice | Intervention Type: BEHAVIORAL; Name: Outcome Incentive arm; Assigned to Arm(s): Outcome Incentive arm | Intervention Type: BEHAVIORAL; Name: Loss framing incentive arm; Assigned to Arm(s): Loss framing incentive arm | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Non-Inferiority Trial ComparingCigarette Consumption, Adoption Rates, Acceptability, Tolerability, and Tobacco Harm Reduction Potential in Smokers Switching to Heated Tobacco Products or Electronic Cigarettes: Study Protocol
Brief Summary: This is a 12-weeks, open label, non-inferiority trial comparing HTPs vs ECs in terms of efficacy, adoption rate and acceptability, tolerability, and tobacco harm reduction in 220 healthy smokers, not motivated to quit, randomized (1:1) to switch to one of these products. The duration of the study, from the enrollment to the study close out for all the patients at week 24 (follow-up), will be approximately 12 months. Enrollment period will last about 6 months with the support of a multi-channel advertising method. This will include location-based advertising on social networks, advertising in local media, information days organized within the city.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
D: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Non-Inferiority Trial ComparingCigarette Consumption, Adoption Rates, Acceptability, Tolerability, and Tobacco Harm Reduction Potential in Smokers Switching to Heated Tobacco Products or Electronic Cigarettes: Study Protocol
Brief Summary: This is a 12-weeks, open label, non-inferiority trial comparing HTPs vs ECs in terms of efficacy, adoption rate and acceptability, tolerability, and tobacco harm reduction in 220 healthy smokers, not motivated to quit, randomized (1:1) to switch to one of these products. The duration of the study, from the enrollment to the study close out for all the patients at week 24 (follow-up), will be approximately 12 months. Enrollment period will last about 6 months with the support of a multi-channel advertising method. This will include location-based advertising on social networks, advertising in local media, information days organized within the city.


Options:
A: Arm Label: E-Cigarette; Type: EXPERIMENTAL; Interventions: Other: E-Cigarette Vs. Smoking as Usual | Arm Label: Assessment Only; Type: ACTIVE_COMPARATOR; Interventions: Other: E-Cigarette Vs. Smoking as Usual | Intervention Type: OTHER; Name: E-Cigarette Vs. Smoking as Usual; Assigned to Arm(s): Assessment Only, E-Cigarette
B: Arm Label: HIGH NICOTINE; Type: N/A; Interventions: N/A
C: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
D: Arm Label: Nicotine E-Cigarette and Counseling; Type: EXPERIMENTAL; Interventions: Other: Nicotine E-Cigarette, Behavioral: Counseling | Arm Label: Non-Nicotine E-Cigarette and Counseling; Type: OTHER; Interventions: Other: Non-Nicotine E-Cigarette, Behavioral: Counseling | Arm Label: Counseling; Type: OTHER; Interventions: Behavioral: Counseling | Intervention Type: OTHER; Name: Nicotine E-Cigarette; Assigned to Arm(s): Nicotine E-Cigarette and Counseling | Intervention Type: OTHER; Name: Non-Nicotine E-Cigarette; Assigned to Arm(s): Non-Nicotine E-Cigarette and Counseling | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Counseling, Nicotine E-Cigarette and Counseling, Non-Nicotine E-Cigarette and Counseling

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Non-Inferiority Trial ComparingCigarette Consumption, Adoption Rates, Acceptability, Tolerability, and Tobacco Harm Reduction Potential in Smokers Switching to Heated Tobacco Products or Electronic Cigarettes: Study Protocol
Brief Summary: This is a 12-weeks, open label, non-inferiority trial comparing HTPs vs ECs in terms of efficacy, adoption rate and acceptability, tolerability, and tobacco harm reduction in 220 healthy smokers, not motivated to quit, randomized (1:1) to switch to one of these products. The duration of the study, from the enrollment to the study close out for all the patients at week 24 (follow-up), will be approximately 12 months. Enrollment period will last about 6 months with the support of a multi-channel advertising method. This will include location-based advertising on social networks, advertising in local media, information days organized within the city.


Options:
A: Arm Label: Nicotine E-Cigarette and Counseling; Type: EXPERIMENTAL; Interventions: Other: Nicotine E-Cigarette, Behavioral: Counseling | Arm Label: Non-Nicotine E-Cigarette and Counseling; Type: OTHER; Interventions: Other: Non-Nicotine E-Cigarette, Behavioral: Counseling | Arm Label: Counseling; Type: OTHER; Interventions: Behavioral: Counseling | Intervention Type: OTHER; Name: Nicotine E-Cigarette; Assigned to Arm(s): Nicotine E-Cigarette and Counseling | Intervention Type: OTHER; Name: Non-Nicotine E-Cigarette; Assigned to Arm(s): Non-Nicotine E-Cigarette and Counseling | Intervention Type: BEHAVIORAL; Name: Counseling; Assigned to Arm(s): Counseling, Nicotine E-Cigarette and Counseling, Non-Nicotine E-Cigarette and Counseling
B: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
C: Arm Label: E-Cigarette 7.2 mg nicotine; Type: EXPERIMENTAL; Interventions: Device: E-Cigarette 7.2 mg nicotine | Intervention Type: DEVICE; Name: E-Cigarette 7.2 mg nicotine; Assigned to Arm(s): E-Cigarette 7.2 mg nicotine
D: Arm Label: Traditional cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Arm Label: Electronic cigarette; Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Arm Label: Heat-not-burn tobacco products (IQOS); Type: EXPERIMENTAL; Interventions: Behavioral: Smoke | Intervention Type: BEHAVIORAL; Name: Smoke; Assigned to Arm(s): Electronic cigarette, Heat-not-burn tobacco products (IQOS), Traditional cigarette

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Non-Inferiority Trial ComparingCigarette Consumption, Adoption Rates, Acceptability, Tolerability, and Tobacco Harm Reduction Potential in Smokers Switching to Heated Tobacco Products or Electronic Cigarettes: Study Protocol
Brief Summary: This is a 12-weeks, open label, non-inferiority trial comparing HTPs vs ECs in terms of efficacy, adoption rate and acceptability, tolerability, and tobacco harm reduction in 220 healthy smokers, not motivated to quit, randomized (1:1) to switch to one of these products. The duration of the study, from the enrollment to the study close out for all the patients at week 24 (follow-up), will be approximately 12 months. Enrollment period will last about 6 months with the support of a multi-channel advertising method. This will include location-based advertising on social networks, advertising in local media, information days organized within the city.


Options:
A: Arm Label: THS 2.2; Type: EXPERIMENTAL; Interventions: Other: THS 2.2 | Arm Label: CC; Type: ACTIVE_COMPARATOR; Interventions: Other: CC | Intervention Type: OTHER; Name: THS 2.2; Assigned to Arm(s): THS 2.2 | Intervention Type: OTHER; Name: CC; Assigned to Arm(s): CC
B: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
C: Arm Label: Tobacco-Heating Cigarette; Type: EXPERIMENTAL; Interventions: Other: Tobacco-Heating Cigarette | Arm Label: Snus (Smokeless Tobacco); Type: EXPERIMENTAL; Interventions: Other: Snus (Smokeless Tobacco) | Arm Label: Tobacco-Burning Cigarette; Type: EXPERIMENTAL; Interventions: Other: Tobacco-Burning Cigarette | Intervention Type: OTHER; Name: Tobacco-Heating Cigarette; Assigned to Arm(s): Tobacco-Heating Cigarette | Intervention Type: OTHER; Name: Snus (Smokeless Tobacco); Assigned to Arm(s): Snus (Smokeless Tobacco) | Intervention Type: OTHER; Name: Tobacco-Burning Cigarette; Assigned to Arm(s): Tobacco-Burning Cigarette
D: Arm Label: CHTP 1.0; Type: EXPERIMENTAL; Interventions: Other: CHTP 1.0 | Arm Label: Conventional cigarette (CC); Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Cigarette (CC) | Intervention Type: OTHER; Name: CHTP 1.0; Assigned to Arm(s): CHTP 1.0 | Intervention Type: OTHER; Name: Conventional Cigarette (CC); Assigned to Arm(s): Conventional cigarette (CC)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Effects of Four Weeks of Intermittent Fasting on Resting Energy Expenditure, Satiety Hormones, Body Composition, and Performance in Competitive Runners
Brief Summary: This is a cross-over intervention study designed to evaluate how four weeks of time restricted feeding (16 hours fasting and 8 hours feeding), compared to four weeks of a more traditional eating pattern (12 hours fasting and 12 hours feeding), affects resting energy expenditure, subjective and biochemical markers of satiety and hunger, body composition, cardiovascular health, substrate utilization and fitness in male competitive runners.


Options:
A: Intervention Type: BEHAVIORAL; Name: Dietary composition and energy intake; Assigned to Arm(s): N/A
B: Arm Label: Intermittent Energy Restriction; Type: EXPERIMENTAL; Interventions: Behavioral: Intermittent Energy Restriction | Arm Label: Continuous Energy Restriction; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Continuous Energy Restriction | Intervention Type: BEHAVIORAL; Name: Intermittent Energy Restriction; Assigned to Arm(s): Intermittent Energy Restriction | Intervention Type: BEHAVIORAL; Name: Continuous Energy Restriction; Assigned to Arm(s): Continuous Energy Restriction
C: Arm Label: Experimental Group 1; Type: EXPERIMENTAL; Interventions: Behavioral: Time Restrictive Feeding, Behavioral: Traditional Eating Pattern | Arm Label: Experimental Group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Time Restrictive Feeding, Behavioral: Traditional Eating Pattern | Intervention Type: BEHAVIORAL; Name: Time Restrictive Feeding; Assigned to Arm(s): Experimental Group 1, Experimental Group 2 | Intervention Type: BEHAVIORAL; Name: Traditional Eating Pattern; Assigned to Arm(s): Experimental Group 1, Experimental Group 2
D: Arm Label: Fasting Day First; Type: OTHER; Interventions: Behavioral: Fasting First | Arm Label: Fed Day First; Type: OTHER; Interventions: Behavioral: Fed First | Intervention Type: BEHAVIORAL; Name: Fasting First; Assigned to Arm(s): Fasting Day First | Intervention Type: BEHAVIORAL; Name: Fed First; Assigned to Arm(s): Fed Day First

Answer: C